SCHEMBL5455249

SCHEMBL5455249

CCOc1ccc(NC(=O)Nc2sc3c(c2C(N)=O)CCC2(C3)OCCO2)cc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 10/20 0.50
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
EPHB4 P54760 1/20 0.48
TNIK Q9UKE5 1/20 0.47
PTPN1 P18031 1/20 0.47
TLR2 O60603 2/20 0.45
MAPT P10636 2/20 0.45
FLT3 P36888 1/20 0.44
KDM4E B2RXH2 1/20 0.44
USP2 O75604 1/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
ATM Q13315 1/20 0.44
THRB P10828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5451995 0.90 FLT3 (0.51) KCNH2MEN1KMT2ANPC1RAB9A
SCHEMBL5460583 0.86 FLT3 (0.53) KCNH2MEN1KMT2ANPC1RAB9A
SCHEMBL5451290 0.85 PTPN1 (0.47) KCNH2MEN1KMT2ANPC1RAB9A
SCHEMBL5459253 0.85 PTPN1 (0.52) KCNH2MEN1KMT2ANPC1RAB9A
SCHEMBL5447449 0.85 KMT2A (0.53) KCNH2MEN1KMT2ANPC1RAB9A
SCHEMBL5448343 0.85 MEN1 (0.63) KCNH2MEN1KMT2ANPC1RAB9A
SCHEMBL5457892 0.83 CFTR (0.56) KCNH2MEN1KMT2ANPC1RAB9A
SCHEMBL5455882 0.82 PTPN1 (0.49) KCNH2MEN1KMT2ANPC1RAB9A
SCHEMBL5458993 0.80 POLB (0.59) MEN1KMT2APTPN1MAPTFLT3
SCHEMBL5467916 0.79 FLT3 (0.52) KCNH2MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 KCNH2 3409/4885MEN1 2891/4885KMT2A 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.